Regulatory update for REZONIC™ (casopitant mesylate)

GlaxoSmithKline (NYSE: GSK) confirmed today that it has received a complete response letterfrom the FDA related to the application for casopitant

GlaxoSmithKline (NYSE: GSK) confirmed today that it has received a complete response letterfrom the FDA related to the application for casopitant. 

The company is reviewing this letter and will engage with the FDA to determine appropriate next steps.

A complete response letter is issued by FDA’s Center for Drug Evaluation and Research (CDER) when the review of a file is completed and questions remain that preclude the approval of the application. 

Casopitant was originally filed with the FDA on 29 May 2008, for the prevention of chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). 

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

Philip Thomson

(020) 8047 5502

 

David Outhwaite

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

 

 

US Media enquiries:

Lisa Behrens

(919) 483 2839

 

Ken Inchausti

(919) 483 2839

 

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

Sally Ferguson

(020) 8047 5543

Gary Davies

(020) 8047 5503

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

Jen Hill Baxter

(215) 751 7002

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS